Published in Gynecol Oncol on June 01, 2003
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A (2014) 1.95
Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst (2014) 1.02
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst (2014) 0.99
Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer (2004) 0.91
Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Fam Cancer (2004) 0.88
Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients. Hered Cancer Clin Pract (2016) 0.81
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Hered Cancer Clin Pract (2009) 0.79
Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden. Fam Cancer (2007) 0.76
Genetic risk and gynecologic cancers. Hematol Oncol Clin North Am (2012) 0.75
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. Front Oncol (2016) 0.75
Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates. J Gynecol Oncol (2017) 0.75
Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med (1991) 7.17
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res (1995) 5.72
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science (1968) 3.69
Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med (1978) 3.64
Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med (1988) 3.62
Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet (1998) 3.61
Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell (1992) 3.20
Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17
A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol (1997) 3.11
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Radiation-induced head and neck tumours. Lancet (1974) 3.05
Can the uptake of breast screening by Asian women be increased? A randomized controlled trial of a linkworker intervention. J Public Health Med (1994) 3.04
Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst (1990) 3.02
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
Managed care: devils, angels, and the truth in between. Health Prog (1999) 2.68
Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ (1998) 2.61
The need for liver transplantation: a nationwide estimate based on consensus review. Lancet (1995) 2.58
Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol (1974) 2.51
Pigmentary epitheliopathy and erythema nodosum. Arch Ophthalmol (1971) 2.39
The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet (1998) 2.32
A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med (1974) 2.29
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet (1997) 2.28
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 2.11
Detection and surveillance of colorectal cancer. JAMA (1989) 2.07
Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease. Circulation (1991) 2.04
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03
Cancer among spouses: review of 195 couples. Cancer (1998) 2.03
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol (2000) 1.98
Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time. J Virol (1996) 1.98
Morbidity, comorbidity, and their association with disability among community-dwelling oldest-old in Israel. J Gerontol A Biol Sci Med Sci (1998) 1.95
Case report. Metastatic pulmonary calcification in renal failure: a new HRCT pattern. Br J Radiol (2002) 1.95
The International Collaborative Study of Maternal Phenylketonuria: status report 1998. Eur J Pediatr (2000) 1.91
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. JAMA (1996) 1.90
Mutations of the Gs alpha-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A (1990) 1.82
Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer (2007) 1.77
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet (2002) 1.77
What price survival? The future of Blue Cross and Blue Shield. JAMA (1998) 1.75
Genotype-phenotype correlations in Peutz-Jeghers syndrome. J Med Genet (2004) 1.73
A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet (1997) 1.71
Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol (2001) 1.69
The uninsured. From dilemma to crisis. JAMA (1991) 1.65
Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab (1996) 1.65
Slicing the pie thinner: hospitals and physicians square off over primary care services. Hospitals (1982) 1.64
The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol (2000) 1.63
Impaired learning in mice with abnormal short-lived plasticity. Curr Biol (1996) 1.63
Prediction of early course of breast carcinoma by thymidine labeling. Cancer (1983) 1.61
Coping with calamity. How well does health care disaster planning work? JAMA (1994) 1.61
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (1999) 1.61
The kin-cohort study for estimating penetrance. Am J Epidemiol (1998) 1.60
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol (2002) 1.60
Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol (1996) 1.59
Evaluation of the appropriateness of blood and blood product transfusion using preset criteria. Transfusion (1989) 1.57
Hyperendemic Streptococcus pyogenes infection despite prophylaxis with penicillin G benzathine. N Engl J Med (1991) 1.57
The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology (2012) 1.56
Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation (2001) 1.56
New evidence for neurotransmitter influences on brain development. Trends Neurosci (1997) 1.53
Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry (1992) 1.53
Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 1.51
Prevalence of HIV antibodies in transsexual and female prostitutes. Am J Public Health (1992) 1.47
ATM haplotypes and breast cancer risk in Jewish high-risk women. Br J Cancer (2006) 1.47
Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain (1999) 1.45
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst (2000) 1.45
Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med (1982) 1.44
Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response. The Israel study of glucose intolerance, obesity and hypertension. Diabetologia (1986) 1.44
A controlled intervention in reduction of redundant hospital days. Int J Epidemiol (1996) 1.44
Risk of brain tumours in relation to estimated RF dose from mobile phones: results from five Interphone countries. Occup Environ Med (2011) 1.43
Sexual knowledge, attitudes, and practice of Israeli adolescents. Am J Public Health (1978) 1.42
Validation of short term recall of mobile phone use for the Interphone study. Occup Environ Med (2006) 1.42
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer (2004) 1.41
The quandary of cancer prevention. J Clin Epidemiol (1994) 1.40
Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. Cancer Res (2000) 1.40
Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science (1992) 1.40
A demanding issue. Healthc Forum J (1996) 1.39
Changing the ranks of medicine. Women MDs. Med World News (1988) 1.39
Smoking--the next-door killer. Isr Med Assoc J (2000) 1.39
Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer (2007) 1.38